NCT07124117View on ClinicalTrials.gov

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

February 8, 2029

Study Completion Date

February 8, 2029

Conditions
Advanced Solid Tumor
Interventions
DRUG

OBI-902

OBI-902 is an antibody-drug conjugate study drug

Trial Locations (6)

116

ACTIVE_NOT_RECRUITING

Wan Fan Hospital, Taipei

23561

ACTIVE_NOT_RECRUITING

Shuang Ho Hospital, Taipei

77030

ACTIVE_NOT_RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

92037

ACTIVE_NOT_RECRUITING

Scripps Green Hospital, La Jolla

404327

ACTIVE_NOT_RECRUITING

China Medical University Hospital, Taichung

Sponsors

Lead Sponsor

OBI Pharma, Inc
All Listed Sponsors
lead

OBI Pharma, Inc

INDUSTRY

NCT07124117 - A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter